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HEALTH ECONOMIC EVALUATION OF PATIENTS WITH
RHEUMATOID ARTHRITIS (RA) TREATED WITH ADALIMUMAB
Vanoverbeke N1, Annemans L1, Cauchie P2, Hendrickx E2
1HEDM, Meise, Belgium; 2Abbott, Ottignies, Belgium
OBJECTIVES: To assess the cost-effectiveness of adalimumab
versus etanercept in the management of Belgian patients with
moderate to severe RA. Adalimumab is a human anti-TNF mon-
oclonal antibody and is administered every other week, in com-
bination with methotrexate (MTX) or other disease-modifying
antirheumatic drugs, or as monotherapy. Two scenarios were
developed: one for which each TNF-antagonist was combined
with MTX, and one for which each was given as monotherapy.
METHODS: An incidence-based Markov model was created in
MS-Excel, reﬂecting the current treatment strategies and their
associated outcomes. ACR response rates were obtained for
adalimumab and etanercept from pivotal clinical trials. After
adjustment for differences in trial populations according to 
the Choi-method, 42.1% of adalimumab-monotherapy patients,
66.7% of adalimumab plus MTX patients, 60.1% of etanercept-
monotherapy patients, and 65.6% of etanercept plus MTX
patients achieved a ≥20% improvement in ACR criteria. Second-
line inﬂiximab therpy and a return to watchful-waiting in case
of inadequate response and/or adverse events were also consid-
ered. Estimated resource use was provided by 6 rheumatologists.
Effectiveness was expressed in QALYs, and calculated according
to a validated method (Boggs) from HAQ-DI scores for ACR20
responders and non-responders. The analysis spanned 3 years.
RESULTS: Etanercept plus MTX and adalimumab plus MTX
generated comparable utilities (1.284 vs. 1.287 QALYs), at a
slightly higher cost for etanercept (38,970€ vs. 38,578€). An
analysis of both as monotherapies resulted in a cost of 28,757€
and 1.138 QALYs for etanercept, and 22,784€ and 1.052 QALYs
for adalimumab. The associated incremental cost-effectiveness
was 69,971€, based on price-parity. Sensitivity analyses showed
that results were sensitive toward variations in AE rates,
response rates of second-line inﬂiximab, and modiﬁcations in the
administration modalities of adalimumab. However, these sensi-
tivities did not affect the comparative results. CONCLUSIONS:
Adalimumab is comparably effective and cost-effective to etan-
ercept, but at a slightly to moderately lower cost.
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A COST MINIMISATION ANALYSE FOR STUDYING THE
EFFICIENCY OF BIOLOGIC THERAPIES (BT) IN RHEUMATOID
ARTHRITIS (RA). OVERVIEW FOR THE SPANISH SETTING
Badia X1, Serrano D1, Magaz S2
1Health Outcomes Research Europe, Barcelona, Barcelona, Spain;
2Health Outcomes Policy and Economics, Barcelona, Spain
OBJECTIVE: Adalimumab is a new fully human anti-TNFá
monoclonal antibody used to treat moderate to severe rheuma-
toid arthritis (RA). Adalimumab, just like the other biological
therapies (BT), for RA, etanercept and inﬂiximab, has proved to
be effective and safe in randomised clinical trials. These BT have
different administration routes and dosage proﬁles so their use
might have a different economic impact for health care budgets.
There is no evidence about the relative efﬁciency of the available
BT in the Spanish setting and the objective of this research was
to undertake an economic evaluation of the three therapies.
METHODS: Under the assumption of similar efﬁcacy rates, a
cost minimisation analysis was performed under the perspective
of the Spanish NHS and a time horizon of 1 year, thus only
including direct health care costs for the administration of the
drugs and the management of adverse events. The adverse events
incidences were classiﬁed as mild, moderate and severe, and were
taken into account as a random variables in order to collect the
uncertainly. A decision-analysis model was developed to simu-
late a cohort of 5000 patients in each iteration so statistically
signiﬁcant differences could be assessed. Data on the incidence
of adverse events with each drug was retrieved from randomised
clinical trials. Data on resource use was extracted from an expert
panel of 2 specialists and data on unit costs from published
sources. RESULTS: The mean costs per patient treated were
17,229€ for inﬂiximab, 14,289€ for etanercept, and 13,845€ for
adalimumab. Differences were statistically signiﬁcant (p = 0.00)
in all 10 simulations that were conducted. CONCLUSION: In
our analyses Adalimumab was the most efﬁcient biologic therapy
in patients with AR, that have failed therapy with at least one
disease-modifying antirheumatic drugs (DMARD’s).
PAR10
PATTERNS OF DOSING WITH ADALIMUMAB AMONG
COMMERCIALLY INSURED PATIENTS
Ollendorf DA, Lidsky L, Zhao J
PharMetrics, Inc, Watertown, MA, USA
OBJECTIVES: To conduct a descriptive examination of patterns
of dosing with adalimumab among a cohort of commercially-
insured patients to assess whether dosing frequency in clinical
practice is consistent with standard labeling. METHODS: Data
were obtained from the PharMetrics Patient-Centric Database,
which contains integrated medical and pharmacy claims data for
approximately 43 million unique patients from 74 health plans
across the U.S. All patients with two or more prescriptions for
adalimumab during the period January–December 2003 were
initially identiﬁed and followed for up to 11 months. Dosing fre-
quency was expressed based on the average number of calendar
days between injections, which was calculated by dividing the
number of elapsed days between prescription claims by the quan-
tity supplied (i.e., number of syringes) for the prescription initi-
ating the interval. Injection frequency was tracked over time
based on patients available at each prescription interval, and was
also measured speciﬁcally among patients with at least six pre-
scription intervals (i.e., seven consecutive prescriptions). For 
this calculation, the percentage of patients with time between
injections that approximated every-week (0–11 days) vs. every-
other-week (12 days or more) dosing was calculated. RESULTS:
A total of 527 patients were available for analysis. The mean 
age of the sample was 51.3 years; 76.1% were female. The
average number of days between injections declined substantially
over time, from 16.2 days at the ﬁrst interval (N = 527) to 12.5
days at the 10th interval (N = 27). As of the sixth interval, 34
patients (23.8%) were receiving injections on an approximate
every-week basis, while the remaining 109 patients (76.2%) were
dosed every other week. CONCLUSIONS: The results of this
analysis suggest that the time between adalimumab injections
may decline over multiple treatments; furthermore, after sub-
stantial use of adalimumab, up to one-quarter of patients may
require injections more frequently than what is stipulated in the
labeling.
PAR11
A COST EFFICACY ANALYSIS ON ANTI-TNF THERAPY IN
ANKYLOSING SPONDYLITIS
Singh G1,Tandon N2, Bala M2
1Stanford University Medical School, Palo Alto, CA, USA; 2Centocor,
Inc, Horsham, PA, USA
OBJECTIVE: To estimate the cost-efﬁcacy of inﬂiximab and
etanercept compared to placebo in patients with ankylosing
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spondylitis (AS). METHODS: Inﬂiximab and etanercept signiﬁ-
cantly improve signs and symptoms of AS. We analyzed their
cost-efﬁcacy based on incremental beneﬁt versus placebo in their
respective AS pivotal trials. Inclusion and exclusion criteria were
similar for both trials except for permitted concomitant medica-
tions. The base model estimates cost efﬁcacy for maintenance
therapy, compared to placebo. Costs were estimated based on
average dose for a patient receiving maintenance therapy over a
1-year period. The average number of inﬂiximab vials per dose
(4) and total doses/year per patient (8) were obtained from
ASSERT trial data. Etanercept was assumed to be administered
at 25mg/dose twice weekly. The ASAS 20, ASAS partial remis-
sion, DCART 20 response rates, and percent improvement in
BASFI at week 24 were used as efﬁcacy measures. RESULTS: In
the inﬂiximab trial, 201 patients received inﬂiximab (5mg/kg)
and 78 patients received placebo. In the etanercept trial, 138
patients were treated with etanercept 25mg twice weekly and
139 received placebo. The cost per responder for inﬂiximab as
measured by ASAS 20, ASAS partial response, and DCART 20
was $44,790, $89,156, and $54,057, respectively. The corre-
sponding costs per responder for etanercept were $43,271,
$116,500, and $58,250. The mean percent improvement in
BASFI in the inﬂiximab and placebo arms were 38.5% and 0.1%
respectively, leading to a cost per percent BASFI improvement of
$490. The corresponding numbers for etanercept were 30% and
2%, leading to a cost per percent BASFI improvement of $541.
CONCLUSIONS: The cost-efﬁcacy ratios of inﬂiximab and
etanercept maintenance therapies compared to placebo were
similar. The cost-effectiveness in clinical practice will depend on
the actual dose and effectiveness achieved. Incremental cost-
effective comparisons cannot be reliably estimated without a
head-to-head trial.
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HOW ADEQUATE DO RA-PATIENTS REPORT INDIRECT
COSTS?—THE EXAMPLE OF A GERMAN COHORT
Mittendorf T1, Merkesdal S2, Greiner W1, Ruof J2
1University of Hannover, Hannover, Germany; 2Medical School of
Hannover, Hannover, Germany
OBJECTIVES: To render information on the accuracy of patient-
reported indirect cost data. By comparing questionnaire-derived
data to payer-derived data on a patient-by-patient basis disease
related productivity losses in rheumatoid arthritis (RA) are being
validated. METHODS: The assessment of indirect cost data was
part of a clinical multicenter randomized RA-trial in Germany.
For 234 RA-patients at working age (1987 ACR criteria, mem-
bership in the regional statutory health insurance plan, mean age
53 (±9) years, mean disease duration 8 (±7) years, 76% females)
every three months corresponding indirect cost data were derived
from (i) a health economic questionnaire for cost assessment in
patients with RA and (ii) the payer’s database (insurance and
physicians’ association) over a period of 18 months. Compara-
tive statistical analyses were performed between patient reported
and insurance claims data. RESULTS: The mean annual pro-
ductivity losses due to sick leave amounted to 14 and 17 days
per patient (questionnaire versus payer data), productivity losses
due to work disability to 3 days (both); monetary valuation
renders overall costs of 1240€ and 1590€, respectively. The dif-
ference of 17% in overall productivity losses is not signiﬁcant.
Comparison of productivity losses reveals a strong correlation of
r = 0.83 in those due to sick leave and of kappa = 0.84 in those
due to work disability between questionnaire and payer data.
CONCLUSIONS: The comparison of questionnaire and payer
data shows that RA-patients report their productivity losses ade-
quately. Indirect cost assessment should therefore be included in
further RA-trials and observational studies, even if payer-derived
data is not available.
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COST-EFFECTIVENESS OF VALDECOXIB COMPARED TO
DICLOFENAC IN PATIENTS WITH RHEUMATOID ARTHRITIS
(RA) IN THE UK (UK) AND GERMANY
Alten RH1, von Scheele B2, Gaffney L3, Maciver F3, Niculescu L4
1Schlossparkklinik, Berlin, Germany; 2RTI Health Solutions, Södra
Sandby, Sweden; 3RTI Health Solutions, Manchester, UK; 4Pﬁzer Inc,
New York, NY, USA
OBJECTIVE: To compare the cost-effectiveness of valdecoxib 20
mg once daily (qd) and diclofenac 75mg slow release (SR) twice
daily (bid) in the treatment of RA based on prospectively col-
lected data of Health Care resource utilization in a randomized
controlled trial (RCT, study 062) over 6 months. The cost-
effectiveness evaluations were calculated for the UK from a
National Health Service payer perspective, and for Germany
from a Sickness funds payer perspective. METHODS: Study 062
compared efﬁcacy and safety of valdecoxib 20mgqd (n = 246)
with diclofenac 75mg SR bid (n = 237) in adult patients with
RA. The cost-effectiveness of valdecoxib and diclofenac was
compared using country-speciﬁc unit costs for resource use (hos-
pital days, medications, unscheduled procedures and health care
visits) in the UK and Germany. The cost-effectiveness ratios were
calculated for cost/averted gastroduodenal (GD) ulcer,
cost/averted withdrawal due to treatment failure and/or adverse
event, cost/averted gastrointestinal (GI) serious adverse event
(SAE), and cost/avoided ulcer with GI SAE. RESULTS: The study
showed comparable efﬁcacy and a superior safety proﬁle for
valdecoxib, resulting in fewer GI adverse events and hospital
days. The cost/averted GD ulcer in the UK was -£1104 and 386€
in Germany. The cost/averted withdrawal due to treatment
failure and/or adverse event was -£1580 in the UK and 553€ in
Germany. The cost/averted GI SAE was -£2709 in the UK and
947€ in Germany, and the cost/avoided ulcer with GI SAE was
-£3522 in the UK and 1436€ in Germany. CONCLUSIONS: The
superior safety proﬁle of valdecoxib compared with diclofenac
translates into lower total health care costs for patients treated
with valdecoxib, and overall cost effectiveness in both countries.
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COSTS OF RA IN GERMANY ON A MICRO-COSTING LEVEL
Mittendorf T1, Ruof J2
1University of Hannover, Hannover, Germany; 2Medical School of
Hannover, Hannover, Germany
OBJECTIVES: To develop a systematic set of German cost data
in RA based solely on valid health care payer’s cost data sources
on a patient—per—patient micro-costing level. METHODS:
Retrospectively one-year cost data of 338 RA patients were gen-
erated and analyzed. The cost data were derived from a major
statutory health insurance plan (“Allgemeine Ortskrankenkasse
Niedersachsen”) and the regional physicians’ association
(“Kassenärztliche Vereinigung Niedersachsen”). A matrix of cost
domains in RA was applied to structure the analysis. Descriptive
statistics were used to analyze the data. RESULTS: The total
direct costs for the 338 patients during the one year period (3rd
quarter 2000—2nd quarter 2001) were 3815€ per patient-year.
RA-related direct costs were 2312€ per patient-year. Outpatient
costs accounted for 73.7%, inpatient costs for 24.0%, and other
disease-related costs for 2.3% of RA-related direct costs. Out-
patients costs drivers were: RA-related medication (1019€ per
patient-year), physician visits (323€ per patient-year), diagnostic
and therapeutic procedures and tests (185€ per patient-year), and
devices and aids (168€ per patient-year). Ninety-eight patients
